Oric Pharmaceuticals (4TZ) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

4TZ Analyst Ratings

Strong Buy

9 Buy

0 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Oric

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

4TZ Stock 12 Month Forecast

Average Price Target

€18.48

▲(62.83% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Oric Pharmaceuticals in the last 3 months. The average price target is €18.48 with a high forecast of €23.15 and a low forecast of €12.00. The average price target represents a 62.83% change from the last price of €11.35.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"€5","24":"€24","9.75":"€9.75","14.5":"€14.5","19.25":"€19.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":23.14900161,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€23.15</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18.481095935555558,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€18.48</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.00318602,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,9.75,14.5,19.25,24],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.85,10.873000123846154,11.896000247692307,12.919000371538461,13.942000495384615,14.96500061923077,15.988000743076924,17.011000866923077,18.03400099076923,19.057001114615385,20.08000123846154,21.103001362307694,22.126001486153847,{"y":23.14900161,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.85,10.513930456581196,11.177860913162393,11.84179136974359,12.505721826324788,13.169652282905982,13.83358273948718,14.497513196068377,15.161443652649574,15.82537410923077,16.489304565811967,17.153235022393165,17.81716547897436,{"y":18.481095935555558,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,9.85,10.015629693846153,10.181259387692307,10.34688908153846,10.512518775384615,10.678148469230768,10.843778163076923,11.009407856923076,11.17503755076923,11.340667244615384,11.506296938461539,11.671926632307692,11.837556326153846,{"y":12.00318602,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.4,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.65,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.2,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.9,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.9,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.1,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.2,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.7,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.986,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.146,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.67,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.85,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€23.15

Average Price Target€18.48

Lowest Price Target€12.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Robert Burns

H.C. Wainwright

€21.43→€23.15

Buy

103.96%

Upside

Reiterated

08/10/26

Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (NASDAQ: ORIC), Janux Therapeutics Inc (NASDAQ: JANX) and Entrada Therapeutics Inc (NASDAQ: TRDA)

Anupam Rama

J.P. Morgan

€19.72

Buy

73.74%

Upside

Reiterated

08/06/26

Oric Pharmaceuticals (ORIC) Gets a Buy from J.P. Morgan

Cory Kasimov

Evercore ISI

€21.43

Buy

88.85%

Upside

Reiterated

08/04/26

Evercore ISI Keeps Their Buy Rating on Oric Pharmaceuticals (ORIC)

Kelsey Goodwin

Piper Sandler

€18.86

Buy

66.19%

Upside

Assigned

08/04/26

Piper Sandler Releases a Buy Rating on Oric Pharmaceuticals (ORIC)

Derek Archila

Wells Fargo

€21.43

Buy

88.85%

Upside

Reiterated

08/04/26

Oric Pharmaceuticals (ORIC) Gets a Buy from Wells Fargo

Boris Peaker

JonesTrading

€21.43

Buy

88.85%

Upside

Reiterated

08/04/26

ORIC Pharmaceuticals: Buy Rating Reaffirmed with Unchanged $25 Price Target on Multiple Oncology Catalysts and mCRPC Upside

Laura Prendergast

Stifel Nicolaus

€12

Buy

5.75%

Upside

Reiterated

08/04/26

Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (NASDAQ: ORIC), ClearPoint Neuro (NASDAQ: CLPT) and Keros Therapeutics (NASDAQ: KROS)

Bradley Canino

Guggenheim

€15.43

Buy

35.97%

Upside

Reiterated

08/03/26

Analysts' Top Healthcare Picks: Oric Pharmaceuticals (ORIC), AbbVie (ABBV)

Corinne Johnson

Goldman Sachs

€12.86

Buy

13.31%

Upside

Reiterated

06/02/26

Analysts Offer Insights on Healthcare Companies: Ardent Health Partners, Inc. (NYSE: ARDT), Tactile Systems Technology (NASDAQ: TCMD) and Oric Pharmaceuticals (NASDAQ: ORIC)

Unknown Analyst

Wedbush

Not Ranked

Wedbush

€14.58

Buy

28.42%

Upside

Initiated

05/05/26

Oric Pharmaceuticals (ORIC) Initiated with a Buy at Wedbush

Yigal Nochomovitz

Citi

€14.58→€13.72

Buy

20.86%

Upside

Assigned

05/05/26

Oric Pharmaceuticals price target lowered to $16 from $17 at CitiOric Pharmaceuticals price target lowered to $16 from $17 at Citi

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

€12.86

Buy

13.31%

Upside

Reiterated

12/08/25

Roth MKM Reaffirms Their Buy Rating on Oric Pharmaceuticals (ORIC)

Unknown Analyst

Wolfe Research

Not Ranked

Wolfe Research

―

Hold

―

Initiated

11/17/25

Oric Pharmaceuticals initiated with a Peer Perform at Wolfe ResearchOric Pharmaceuticals initiated with a Peer Perform at Wolfe Research

Kevin DeGeeter

Ladenburg Thalmann & Co.

€12.86

Buy

13.31%

Upside

Reiterated

11/14/25

Oric Pharmaceuticals (ORIC) Gets a Buy from Ladenburg Thalmann & Co.

Prakhar Agrawal

Cantor Fitzgerald

―

Buy

―

Reiterated

09/26/25

Oric Pharmaceuticals (ORIC) Receives a Buy from Cantor Fitzgerald

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Robert Burns

H.C. Wainwright

€21.43→€23.15

Buy

103.96%

Upside

Reiterated

08/10/26

Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (NASDAQ: ORIC), Janux Therapeutics Inc (NASDAQ: JANX) and Entrada Therapeutics Inc (NASDAQ: TRDA)

Anupam Rama

J.P. Morgan

€19.72

Buy

73.74%

Upside

Reiterated

08/06/26

Oric Pharmaceuticals (ORIC) Gets a Buy from J.P. Morgan

Cory Kasimov

Evercore ISI

€21.43

Buy

88.85%

Upside

Reiterated

08/04/26

Evercore ISI Keeps Their Buy Rating on Oric Pharmaceuticals (ORIC)

Kelsey Goodwin

Piper Sandler

€18.86

Buy

66.19%

Upside

Assigned

08/04/26

Piper Sandler Releases a Buy Rating on Oric Pharmaceuticals (ORIC)

Derek Archila

Wells Fargo

€21.43

Buy

88.85%

Upside

Reiterated

08/04/26

Oric Pharmaceuticals (ORIC) Gets a Buy from Wells Fargo

Boris Peaker

JonesTrading

€21.43

Buy

88.85%

Upside

Reiterated

08/04/26

ORIC Pharmaceuticals: Buy Rating Reaffirmed with Unchanged $25 Price Target on Multiple Oncology Catalysts and mCRPC Upside

Laura Prendergast

Stifel Nicolaus

€12

Buy

5.75%

Upside

Reiterated

08/04/26

Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (NASDAQ: ORIC), ClearPoint Neuro (NASDAQ: CLPT) and Keros Therapeutics (NASDAQ: KROS)

Bradley Canino

Guggenheim

€15.43

Buy

35.97%

Upside

Reiterated

08/03/26

Analysts' Top Healthcare Picks: Oric Pharmaceuticals (ORIC), AbbVie (ABBV)

Corinne Johnson

Goldman Sachs

€12.86

Buy

13.31%

Upside

Reiterated

06/02/26

Analysts Offer Insights on Healthcare Companies: Ardent Health Partners, Inc. (NYSE: ARDT), Tactile Systems Technology (NASDAQ: TCMD) and Oric Pharmaceuticals (NASDAQ: ORIC)

Unknown Analyst

Wedbush

Not Ranked

Wedbush

€14.58

Buy

28.42%

Upside

Initiated

05/05/26

Oric Pharmaceuticals (ORIC) Initiated with a Buy at Wedbush

Yigal Nochomovitz

Citi

€14.58→€13.72

Buy

20.86%

Upside

Assigned

05/05/26

Oric Pharmaceuticals price target lowered to $16 from $17 at CitiOric Pharmaceuticals price target lowered to $16 from $17 at Citi

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

€12.86

Buy

13.31%

Upside

Reiterated

12/08/25

Roth MKM Reaffirms Their Buy Rating on Oric Pharmaceuticals (ORIC)

Unknown Analyst

Wolfe Research

Not Ranked

Wolfe Research

―

Hold

―

Initiated

11/17/25

Oric Pharmaceuticals initiated with a Peer Perform at Wolfe ResearchOric Pharmaceuticals initiated with a Peer Perform at Wolfe Research

Kevin DeGeeter

Ladenburg Thalmann & Co.

€12.86

Buy

13.31%

Upside

Reiterated

11/14/25

Oric Pharmaceuticals (ORIC) Gets a Buy from Ladenburg Thalmann & Co.

Prakhar Agrawal

Cantor Fitzgerald

―

Buy

―

Reiterated

09/26/25

Oric Pharmaceuticals (ORIC) Receives a Buy from Cantor Fitzgerald

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ODTXOdyssey Therapeutics, Inc.

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

GPCRStructure Therapeutics, Inc. Sponsored ADR

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Oric Pharmaceuticals

3 Months

Derek ArchilaWells Fargo

Success Rate

6/10 ratings generated profit

Average Return

+12.98%

Copying Derek Archila's trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +12.98% per trade.

1 Year

Anupam RamaJ.P. Morgan

Success Rate

15/18 ratings generated profit

Average Return

+35.13%

Copying Anupam Rama's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +35.13% per trade.

2 Years

Derek ArchilaWells Fargo

Success Rate

9/10 ratings generated profit

Average Return

+37.70%

Copying Derek Archila's trades and holding each position for 2 Years would result in 90.00% of your transactions generating a profit, with an average return of +37.70% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

4TZ Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 4TZ has received 14 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 4TZ average Analyst price target in the past 3 months is 18.48.

Each month's total comprises the sum of three months' worth of ratings.

4TZ Financial Forecast

4TZ Earnings Forecast

Next quarter’s earnings estimate for 4TZ is -€0.33 with a range of -€0.39 to -€0.28. The previous quarter’s EPS was -€0.33. 4TZ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 4TZ has Performed in-line its overall industry.

No data currently available

4TZ Sales Forecast

Next quarter’s sales forecast for 4TZ is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. 4TZ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 4TZ has Performed in-line its overall industry.

4TZ Stock Forecast FAQ

What is DE:4TZ’s average 12-month price target, according to analysts?

Based on analyst ratings, Oric Pharmaceuticals’s 12-month average price target is 18.48.

What is DE:4TZ’s upside potential, based on the analysts’ average price target?

Oric Pharmaceuticals has 62.83% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Oric Pharmaceuticals a Buy, Sell or Hold?

Oric Pharmaceuticals has a consensus rating of Strong Buy, which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.

What is Oric Pharmaceuticals’s share price target?

The average share price target for Oric Pharmaceuticals is 18.48. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €23.15 ,and the lowest forecast is €12.00. The average share price target represents 62.83% Increase from the current price of €11.35.

What do analysts say about Oric Pharmaceuticals?

Oric Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of Oric Pharmaceuticals?

To buy shares of DE:4TZ, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Oric Pharmaceuticals (4TZ) Stock Forecast & Price Target

4TZ Analyst Ratings

4TZ Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Oric Pharmaceuticals

4TZ Analyst Recommendation Trends

4TZ Financial Forecast

4TZ Earnings Forecast

4TZ Sales Forecast

4TZ Stock Forecast FAQ

Detailed List of Analyst Forecasts